International Journal of Gastroenterology Disorders & Therapy Volume 3 (2016), Article ID 3:IJGDT-124, 2 pages
https://doi.org/10.15344/2393-8498/2016/124
https://doi.org/10.15344/2393-8498/2016/124
Commentary
Biosimilars in Gastroenterology- An Important Moment in the Treatment of Inflammatory Bowel Diseases
References
- Park DI (2016) Current status of biosimilars in the treatment of inflammatory bowel diseases. Intest Res 14: 15-20. View
- Szymanska E, Dadalski M, Szymanska S, Grajkowska W, Pronicki M, et al. (2016) The impact of induction therapy with three doses of infliximab on deep histological healing in paediatric patients with active Crohn’s disease. Prz Gastroenterology 11: 176-180. View
- Lee JF, Litten JB, Grampp G (2012) Comparability and biosimilarity: considerations for the healthcare provider. Curr Med Res Opin 28: 1053- 1058. View
- Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, et al. (2013) A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infiximab when co administered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 72: 1613-1620. View
- Mularczyk A, Gonciarz M, Bartnik W, Durlik M, Eder P, et al. (2014) Biosimilar medicines – their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in Gastroenterology. Prz Gastroenterol 9: 1-3. View
- Teixeira FV, Kotze PG, Damiăo AO, Miszputen SJ (2015) Biosimilars in inflammatory bowel diseases: an important moment for Brazilian gastroenterologists. Arq Gastroenterol 52: 76-80. View
- Park SH, Kim YH, Lee JH, Kwon HJ, Lee SH, et al. (2015) Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev Gastroenterol Hepatol 9 Suppl 1: 35-44. View
- Sieczkowska J, Jarzębicka D, Meglicka M, Oracz G, Kierkus J (2016) Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases. Therap Adv Gastroenterol 9: 729-735. View
- Jung YS, Park DI, Kim YH, Lee JH, Seo PJ, et al. (2015) Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study. J Gastroenterol Hepatol 30: 1705-1712. View
- Gecse KB, Lovász BD, Farkas K, Banai J, Bene L et al. (2016) Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.J Crohn’s Colitis.10: 133-140. View
- Farkas K, Rutka M, Golovics PA, Végh Z, Lovász BD, et al. (2016) Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis. J Crohns Colitis 10: 1273-1278. View
- Kaniewska M, Rydzewska G (2016) P519 Efficacy and safety of biosimilar of infliximab (Inflectra)in adult patients with Crohn disease during one year of the treatment followed 6 months of observation - one center retrospective study. J Crohn’s Colits 10: S363. View
- Kaniewska M, Rydzewska G (2016) P645 Efficacy and safety of biosimilar of infliximab in rescue therapy in adult patients with severe ulcerative colitis. J Crohn’s Colitis 10: S428. View
- Buer LC, Moum BA, Cvancarova M, et al. (2016) Switching from Remicade® to Remsima® is well tolerated and feasible: a prospective, open-label study. J Crohns Colitis. View
- Danese S, Fiorino G, Michetti P (2016) Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey. J Crohns Colitis 10: 1362-1365. View